ClinicalTrials.gg
CompletedNCT04766398Updated Oct 28, 2021

Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis

A Phase 3 interventional study of KHK7791 and Placebo in Hyperphosphatemia, sponsored by Kyowa Kirin Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-10-28.

Sponsored by Kyowa Kirin Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
169
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing tenapanor in Hyperphosphatemia — none open to participants now, none under way, none of them phase 3. tenapanor · Hyperphosphatemia.

Enrollment
8th of 13
169 · median 172
Started
2021
with 3 others
Phase 3
6 of 13
none open now
Registered
10th of 13
by date
Lead sponsor
7 of 13
Kyowa Kirin Co., Ltd.

Among the 13 studies testing tenapanor in Hyperphosphatemia, this one is the 8th largest by enrollment, is one of 4 that started in 2021, is one of 6 in phase 3, and was the 10th registered.

Hyperphosphatemia

173 studies on the registry are indexed under Hyperphosphatemia; 16 are open to participants now.

Browse Hyperphosphatemia studies →

Open to participants now

None of the 13 studies testing tenapanor in Hyperphosphatemia is open now. The open studies under Hyperphosphatemia, anywhere →

About tenapanor

tenapanor: first FDA approval 2019 (IBSRELA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 13 Hyperphosphatemia studies recruiting now, 11 (85%) set no upper age limit and 2 (15%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing tenapanor in Hyperphosphatemia as a file.
02

Study summary

To evaluate the efficacy of KHK7791 in combination with phosphate binders by comparing changes in serum phosphorus levels between hemodialysis patients with hyperphosphatemia receiving repeated administration of KHK7791 30 mg in combination with phosphate binders for 6 weeks and those receiving placebo in combination with phosphate binders.

03

Conditions studied

  • Hyperphosphatemia

Browse trials for

Keywords

  • Tenapanor
  • Hyperphosphatemia
  • Hemodialysis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has voluntarily provided written to participate in the study.
  2. Aged ≥ 20 years (expressed in completed years) at the time of providing informed consent.
  3. Stable chronic renal failure patients who have undergone hemodialysis 3 times per week for at least 12 weeks until screening examination.
  4. Dialysis conditions, excluding dry weight, should have been unchanged during the last 2 weeks before screening examination.
  5. The prescribed drug and dosage regimen should have been unchanged during the last 4 weeks before screening examination.
  6. Serum phosphorus levels should be in the range of ≥ 3.5 and ≤ 6.0 mg/dL at screening examination.
  7. If on any vitamin D, calcimimetics regimen, bisphosphonate,calcitonin preparations, selective estrogen receptor modulators or teriparatide preparations then the prescribed drug and dosage regimen should have been unchanged for the last 4 weeks before screening examination.
  8. Kt/V urea ≥ 1.2 at the most recent test in routine medical practice before screening examination.

Exclusion criteria

Exclusion Criteria:

  1. Peritoneal dialysis was performed within 12 weeks before screening examination.
  2. iPTH >600 pg/mL (should be based on the most recent value from the patients' medical records, etc. before pre-enrollment)
  3. Having concurrent or a history of inflammatory bowel disease (IBD) or diarrhea-predominant irritable bowel syndrome
  4. History of gastrectomy or enterectomy or having undergone gastrointestinal tract surgery within 3 months before screening examination.
  5. Subjects who used anti RANKL preparations within 6 weeks before screening examination.
  6. Subjects who used anti-sclerostin antibody preparations within 12 weeks before screening examination.
  7. Having concurrent severe heart disease or hepatic impairment.
  8. Developed cerebrovascular disease requiring hospitalization within 6 months before screening examination.
  9. Uncontrollable hypertension or diabetes.
  10. Scheduled for living donor kidney transplant, change in the mode of dialysis, home hemodialysis, or change in the dialysis center (relocate to another hospital/clinic) during the study period.
  11. Any diagnosis of and treatment of within 5 years before screening examination (excluding basal cell carcinoma or surgically resected intraepithelial carcinoma of uterine cervix).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
169 participants (actual)

Study arms

  • Active comparator
    KHK7791

    During the dosing period, subjects administer the study drug (KHK7791 or placebo) twice daily just before meals in a double blind. The starting dose of the study drug is 5 mg at a time, and the dose is adjusted in the range of 5, 10, 20, and 30 mg at a time based on the dose adjustment criteria described in the study protocol. Dosage adjustment is performed step by step.

    Drug: KHK7791

  • Placebo comparator
    Placebo

    During the dosing period, subjects administer the study drug (KHK7791 or placebo) twice daily just before meals in a double blind. The starting dose of the study drug is 5 mg at a time, and the dose is adjusted in the range of 5, 10, 20, and 30 mg at a time based on the dose adjustment criteria described in the study protocol. Dosage adjustment is performed step by step.

    Drug: Placebo

Interventions

  • oral administration

  • DrugPlacebo

    oral administration

06

What researchers measure

Primary outcomes

  1. Changes in serum phosphorous levels from baseline values at 8 weeks after the start of administration.

    Time frame: Week 8

Secondary outcomes

  1. Changes in serum phosphorous levels from baseline values at each time point.

    Time frame: Dose period, Week 1, 2, 3, 4, 5, 6, 7, 8.

  2. Achievement/failure of the target serum phosphorus level (serum phosphorus level: ≤ 6.0).

    Time frame: Dose period, Week 1, 2, 3, 4, 5, 6, 7, 8.

  3. Time when the target serum phosphorus level (serum phosphorus level: ≤ 6.0) was achieved.

    Time frame: Dose period, Week 1, 2, 3, 4, 5, 6, 7, 8.

  4. Achievement/failure of the target serum phosphorus level (serum phosphorus level: ≤ 5.5).

    Time frame: Dose period, Week 1, 2, 3, 4, 5, 6, 7, 8.

  5. Time when the target serum phosphorus level (serum phosphorus level: ≤ 5.5) was achieved.

    Time frame: Dose period, Week 1, 2, 3, 4, 5, 6, 7, 8.

  6. Concentrations of such as Ca × P product levels at each time point.

    Time frame: Dose period, Week 1, 2, 3, 4, 5, 6, 7, 8.

  7. Changes of such as Ca × P product levels from baseline values at each time point.

    Time frame: Dose period, Week 1, 2, 3, 4, 5, 6, 7, 8.

07

Study locations

1 site
  • Inoue Hospital
    Suita, Osaka, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Sep 2021, 6 months.

Of 21 phase 3 interventional studies under Hyperphosphatemia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 22. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2021
First posted
Feb 23, 2021
StartActual
Mar 15, 2021
Primary completionActual
Sep 27, 2021
CompletionActual
Sep 27, 2021
Last update
Oct 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04766398
Responsible party
Sponsor
First posted
Feb 23, 2021
Start date
Mar 15, 2021
Primary completion
Sep 27, 2021
Completion
Sep 27, 2021
Last update
Oct 28, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenapanor

Start the discussion